MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, INAB had -$2,535K decrease in cash & cash equivalents over the period. -$3,524K in free cash flow.

Cash Flow Overview

Change in Cash
-$2,535K
Free Cash flow
-$3,524K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-3,854 -10,644
Depreciation and amortization
244 511
Non-cash stock-based compensation
692 1,786
Amortization of financing lease right-of-use assets
126 526
Amortization of operating lease right-of-use assets
157 416
Loss on disposal of construction in progres
0 -
Prepaid expenses and other current assets
564 -943
Other non-current assets
-106 0
Accounts payable
-175 -10
Accrued expenses and other current liabilities
-217 -412
Short-term operating lease liabilities
201 225
Long-term operating lease liabilities
-240 -390
Net cash used in operating activities
-3,524 -7,049
Purchases of property and equipment
0 0
Construction in progress
0 0
Net cash used in investing activities
0 0
Payment of issuance costs from december 2023 issuance of common stock
0 0
Proceeds from the issuance of common stock, net of issuance costs
1,112 7,352
Proceeds from the exercise of series c warrants, net of issuance costs-Series ABWarrants
0 1,884
Proceeds from the exercise of series c warrants, net of issuance costs-Series CWarrants
0 383
Principal payments on financing leases
123 459
Net cash provided by financing activities
989 9,160
Net (decrease) in cash and restricted cash
-2,535 2,111
Cash and cash equivalents at beginning of period
11,386 -
Cash and cash equivalents at end of period
10,962 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

IN8BIO, INC. (INAB)

IN8BIO, INC. (INAB)